Oliver Luxxe Assets LLC Boosts Holdings in Globus Medical, Inc. $GMED

Key Points

• Oliver Luxxe Assets increased its Globus Medical position by 47.3% in the second quarter, ending with 42,576 shares valued at approximately $3.36 million. Institutional investors collectively own 95.16% of the company.
• Globus Medical exceeded second-quarter expectations with adjusted EPS of $1.34 and revenue of $789.6 million, while revenue rose 5.9% year over year. Management raised fiscal 2026 EPS guidance to $4.95–$5.05 but kept revenue guidance near $3.2 billion.
• Analysts maintain a generally favorable view, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $101.77, although several firms recently lowered their targets. Execution risks involving Nevro and Enabling Technologies, along with a director’s sale of 25,000 shares, remain potential concerns.

Oliver Luxxe Assets LLC grew its position in Globus Medical, Inc. (NYSE:GMED - Free Report) by 47.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,576 shares of the medical device company's stock after acquiring an additional 13,670 shares during the quarter. Oliver Luxxe Assets LLC's holdings in Globus Medical were worth $3,364,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in GMED. Elevation Wealth Partners LLC grew its holdings in Globus Medical by 2,178.6% during the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company's stock valued at $25,000 after purchasing an additional 305 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Globus Medical during the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC grew its stake in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock valued at $27,000 after buying an additional 197 shares during the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company's stock worth $29,000 after buying an additional 167 shares during the period. Finally, Parallel Advisors LLC raised its holdings in shares of Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock worth $32,000 after buying an additional 173 shares during the period. Institutional investors own 95.16% of the company's stock.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
• Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

Insiders Place Their Bets

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares in the company, valued at $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on GMED. Truist Financial dropped their price objective on Globus Medical from $115.00 to $100.00 and set a "buy" rating for the company in a report on Thursday, July 16th. Wells Fargo & Company decreased their target price on Globus Medical from $103.00 to $99.00 and set an "overweight" rating for the company in a research report on Friday. Stifel Nicolaus lowered their target price on shares of Globus Medical from $95.00 to $80.00 and set a "hold" rating for the company in a research note on Wednesday, July 8th. Weiss Ratings restated a "hold (c+)" rating on shares of Globus Medical in a report on Monday, July 13th. Finally, BMO Capital Markets initiated coverage on shares of Globus Medical in a report on Wednesday, July 8th. They issued an "outperform" rating and a $94.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $101.77.

Globus Medical Stock Up 1.4%

GMED opened at $82.20 on Friday. The stock's fifty day moving average is $79.33 and its two-hundred day moving average is $85.23. The company has a market capitalization of $11.16 billion, a P/E ratio of 21.02, a PEG ratio of 1.70 and a beta of 0.95. Globus Medical, Inc. has a 52 week low of $54.15 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.24. The business had revenue of $789.61 million during the quarter, compared to analysts' expectations of $782.88 million. Globus Medical had a return on equity of 14.73% and a net margin of 17.02%.The business's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities analysts anticipate that Globus Medical, Inc. will post 5 earnings per share for the current year.

Globus Medical Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source